Increasing evidence suggests that gamma interferon (IFN-y) is the major or sole factor in human lymphokines which activates blood monocyte-derived macrophages (M+) to inhibit or kill Toxoplasma gondii and certain other intracellular pathogens. In the current studies, we found that IFN-'y effectively activated tissue M4 from adults (peritoneal M+) and from newborns (placental M+) as well as blood-derived M4 from adults and from newborns to kill or to inhibit the replication of T. gondii. Results with purified and recombinant IFN-y and with adult and newborn M+ were similar. IFN-'y-treated M4 were equally or more active against T. gondii than were freshly isolated monocytes and M+. Recombinant IFN-aA and IFN-IB were less effective than IFN--y. IFN-y also inhibited survival and replication of T. gondii in WISH cells more effectively than did IFN-a and IFN-I. These findings are consistent with an important role for IFN--y in the control of Toxoplasma infection and indicate that the anti-Toxoplasma activity of resting and IFN-.y-activated adult and neonatal M4 is similar. The increased susceptibility of neonates to T. gondii is not due to a defect in M4 effector function.
MATERIALS AND METHODS Reagents. Reagents were obtained from Sigma Chemical Co., St. Louis, Mo., unless otherwise indicated. Hanks balanced salt solution, calf serum, L-glutamine, penicillin, and streptomycin were obtained from GIBCO Laboratories, Grand Island, N.Y. RPMI 1640 containing 25 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) buffer was obtained from MA Bioproducts, Walkersville, Md. When analyzed by the Limulus amebocyte lysate assay (Pyrotell Associates of Cape Cod, Inc., Woods Hole, Mass.), the RPMI 1640 contained <0.06 ng of reference Escherichia coli endotoxin per ml. However, in some assays, RPMI 1640 containing 0.1 to 1.0 ng of endotoxin per ml was used with similar results. Fetal calf serum was obtained from Sterile Systems, Inc., Logan, Utah; it contained 0.07 to 0. 13 Rubin , Sloan Kettering Cancer Institute, Rye, N.Y.; these preparations contained -0.1 ng of reference endotoxin per 1,000 U of activity. Two preparations of rIFN--y from E. coli were provided by Genentech, Inc., San Francisco, Calif.; these preparations lacked detectable endotoxin (<0.06 ng/ml). The standard preparation of rIFN--y is that originally described by Gray et al. (3) ; the second preparation was modified by deleting Cys-Tyr-Cys and adding methionine at the amino-terminal end of the polypeptide (18) . Unless otherwise indicated, the studies described were done with the standard preparation of rIFN-y. rIFN-aA and rIFN-, were obtained from P. Trown, Hoffmann-LaRoche Inc., Nutley, N.J. A human IFN-a standard (G-023-902-527) was obtained from the National Institutes of Health.
Cell preparations. Blood mononuclear cells were obtained by Ficoll-Paque density gradient separation of adult peripheral blood and newborn cord blood as previously described (24, 26 (24) .
Interaction of T. gondii with M4. Monolayers of monocytes and M4 were either used within 2 h of preparation or were cultured in vitro for the intervals indicated before use (see Table 1 ). Fresh peritoneal or placental MX were used either 2 or 18 h after isolation; results with 2-and 18-hcultured cells were similar, so they were pooled. Where indicated, culture supernatants from ConA-stimulated adult blood mononuclear cells (LK) in a final concentration of 30% or IFN preparations in the indicated concentrations were added to monolayers for the indicated intervals before use.
Monolayers of monocytes and M4i were infected with T. gondii, and survival and replication were assessed microscopically or by uptake of [3H]uracil as previously described (8, 9, 27, 28) .
IFN assays. IFN activity was determined by vesicular stomatitis virus plaque reduction as previously described (11, 24) , except that WISH cells rather than fibroblasts were used. Standard preparations of IFN--y were used to determine the IFN content in the rIFN--y and in adult LK; standard preparations of IFN-a were used to determine the IFN content in the rIFN-aA and rIFN-,. Under our assay condition, the IFN contents of the standard and modified rIFN--y were 4.8 x 107 U/ml and 6.7 x 107 U/ml, whereas the supplier indicated their activity to be 1.3 x 107 U/ml and 3.7 X 107 U/ml, respectively. Similarly, under our assay conditions the rIFN-aA and the rIFN-, contained 3.9 x 105 U/ml and 6.7 x 105 U/ml, whereas the supplier indicated their activity to be 6 x 105 U/ml and 1 x 106 U/ml, respectively. The activity indicated in the text is that determined by the supplier.
Statistics. Results are presented as mean + standard deviation (SD). The significance of the differences between means was evaluated by a two-tailed Student's t test or by a paired t test as appropriate (21) .
RESULTS
Concentration-dependent effects of rIFN-,y on intracellular T. gondii. Survival and replication of T. gondii in adult monocyte-derived M4 and placental MX were inhibited by treatment of these cells with rIFN--y in a concentrationdependent manner (Fig. 1) . Maximum effects occurred at 50 to 300 U/ml; greater concentrations of IFN--y were not more effective. As which contained -900 U of IFN per ml, had similar effects at the optimal 30% final concentration (-270 U/ml). Exposure of MX to 300 U of rIFN--y per ml for as little as 4 h had an inhibitory effect on Toxoplasma replication, whereas 24 h was necessary to inhibit survival of T. gondii (data not shown). Maximum inhibition of both occurred after 48 to 72 h of exposure to rIFN-y.
Effects of in vitro culture, LK, and rIFN-y on the interaction of monocytes and M4 with T. gondii. When blood monocyt,s from adults and newborns were cultured in vitro before they-were infected, they became progressively less able to kill-or inhibit the replication of T. gondii (Table 1) . Fresh peritofneal and placental MX were more permissive than fresh monocytes; both became still more permissive after they were cultured in vitro (Table 2) . Exposure to IFN--y enhanced the ability of each type of M4 to kill or inhibit the replication of T. gondii (Tables 1 and   2 (Table 3) .
rIFN-aA inhibited replication of T. gondii in adult monocyte-derived MO and in placental M4 (Table 4) . However, rIFN-aA significantly inhibited (P < 0.05) replication only at concentration of .300 U/ml, whereas rIFN-,y significantly (P < 0.05) inhibited replication at concentrations of .10 U/ml (Table 3) ; the optimum concentration of rIFN-y (300 U/ml) was significantly (P < 0.05) more effective than was the optimal concentration of rIFN-aA (300 to 3,000 U/ml DISCUSSION These results indicate that IFN--y effectively increases the ability of human MP to kill T. gondii and to inhibit the replication of those parasites which survive. Purified and rIFN--y were comparable in their effectiveness; crude LK, when diluted to a 30% final concentration, contained similar amounts of IFN-y (-270 U/ml) and were similar in their effectiveness to the rIFN--y or purified IFN--y preparations. These results are similar to those reported by Nathan et al. (13, 14) with monocyte-derived MW from adult humans and are consistent with their earlier studies (13, 14) and ours (24) , which indicated that the ability of LK to activate MX against T. In contrast to the effects of IFN--y, rIFN-oA only slightly increased the ability of adult or newborn M4s to inhibit T. gondii. replication and did not increase the ability of these M4 to kill T. gondii. rIFN-, did not significantly inhibit survival and replication of T. gondii in M4s. These results are similar to those recently presented by Nathan et al. (14) with M4s derived from adult human monocytes. These authors also found that other cytokines present in crude LK, including interleukin 2, colony-stimulating factor, and MX migration inhibition factor, did not activate M+. Similarly, we have found that purified and recombinant interleukin 2 and purified interleukin 1 do not activate human M4 against T. gondii (unpublished data).
Since T. gondii infects constitutive cells as well as phagocytic cells, we examined the effects of IFNs on the survival and replication of T. gondii in WISH cells, the human cell line in which the antiviral activity of these IFN preparations was determined.
[3H]uracil uptake by Toxoplasma-infected WISH cells treated with rIFN--y was inhibited in a concentration-dependent manner. These results parallel those of Pfefferkorn and Guyre (15) . We found that although rIFN-oaA and rIFN-P, were less effective than rIFN--y, they weakly inhibited [3HJuracil uptake by Toxoplasma-infected WISH cells. These results differ from those of Pfefferkorn and Guyre (15) and Ahronheim (1) in human fibroblasts, but are similar to those of Remington and experiments with rIFN-P, except at concentrations of 3,000 U of rIFN--y per ml and 10 U of rIFN-a and -P per ml (n = 1). Results for IFN-y at 50 and 300 U/ml and rIFN-aA at 50 U/ml were significantly (P <0.05) different than controls.
Merigan (17) with mouse L cells and chicken embryo fibroblasts. The differences in results may reflect differences in IFN preparations, cell types used for the assays, or both. Nevertheless, it is clear that IFN--y is the most potent factor described that enhances the anti-Toxoplasma activity of MX and constitutive cells. These findings underscore the potential importance of IFN-y production in the control of Toxoplasma infection.
Stimulated lymphocytes from neonates produce less IFN--y, with amounts varying from <10 to -60% of that produced by cells of adults (2, 4, 23, 24 
